From the Departments of Neurology and Stroke Units, Helsinki University Central Hospital, Helsinki, Finland (D.S., T.T.); Department of Neurology, University of Heidelberg, Heidelberg, Germany (P.R., W.H.); Department of Neurology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland (P.M., A.E.); Department of Neurology, Universitätsklinikum Erlangen, Erlangen, Germany (L.B., M.K.); Department of Neurology, Tampere University Hospital, Tampere, Finland (J.O., H.N.); Department of Neurology, University Lille Nord de France (K.M., D.L.); Department of Neurology and Stroke Units, University Hospital Basel, Basel, Switzerland (D.J.S., H.G., S.E.); Department of Neurology, University of Bern, Bern, Switzerland (S.J., B.W., H.P.M.); Department of Neurology, Hospital Clínic Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain (V.O., A.C.); and Department of Neurology, Kantonsspital St. Gallen, St. Gallen, Switzerland (B.W.).
Stroke. 2013 Oct;44(10):2913-6. doi: 10.1161/STROKEAHA.111.000819. Epub 2013 Aug 22.
We previously reported increased benefit and reduced mortality after ultra-early stroke thrombolysis in a single center. We now explored in a large multicenter cohort whether extra benefit of treatment within 90 minutes from symptom onset is uniform across predefined stroke severity subgroups, as compared with later thrombolysis.
Prospectively collected data of consecutive ischemic stroke patients who received i.v. thrombolysis in 10 European stroke centers were merged. Logistic regression tested association between treatment delays, as well as excellent 3-month outcome (modified Rankin scale, 0-1), and mortality. The association was tested separately in tertiles of baseline National Institutes of Health Stroke Scale.
In the whole cohort (n=6856), shorter onset-to-treatment time as a continuous variable was significantly associated with excellent outcome (P<0.001). Every fifth patient had onset-to-treatment time≤90 minutes, and these patients had lower frequency of intracranial hemorrhage. After adjusting for age, sex, admission glucose level, and year of treatment, onset-to-treatment time≤90 minutes was associated with excellent outcome in patients with National Institutes of Health Stroke Scale 7 to 12 (odds ratio, 1.37; 95% confidence interval, 1.11-1.70; P=0.004), but not in patients with baseline National Institutes of Health Stroke Scale>12 (odds ratio, 1.00; 95% confidence interval, 0.76-1.32; P=0.99) and baseline National Institutes of Health Stroke Scale 0 to 6 (odds ratio, 1.04; 95% confidence interval, 0.78-1.39; P=0.80). In the latter, however, an independent association (odds ratio, 1.51; 95% confidence interval, 1.14-2.01; P<0.01) was found when considering modified Rankin scale 0 as outcome (to overcome the possible ceiling effect from spontaneous better prognosis of patients with mild symptoms). Ultra-early treatment was not associated with mortality.
I.v. thrombolysis within 90 minutes is, compared with later thrombolysis, strongly and independently associated with excellent outcome in patients with moderate and mild stroke severity.
我们之前曾报道过,在单一中心中,超早期溶栓治疗对脑卒中患者的获益增加,死亡率降低。现在,我们在一个大型多中心队列中探讨了,与后期溶栓相比,在症状发作后 90 分钟内进行额外的治疗是否会对预先设定的脑卒中严重程度亚组产生额外的益处。
合并了 10 个欧洲卒中中心连续入组的接受静脉溶栓治疗的缺血性卒中患者的前瞻性数据。使用逻辑回归检验了治疗延迟以及 3 个月时的良好预后(改良 Rankin 量表 0-1 分)与死亡率之间的相关性。在基线国立卫生研究院卒中量表的三分位数中分别检验了这种相关性。
在整个队列(n=6856)中,发病至治疗时间的连续变量与良好预后显著相关(P<0.001)。每 5 名患者中就有 1 名患者的发病至治疗时间≤90 分钟,这些患者颅内出血的发生率较低。在校正了年龄、性别、入院时血糖水平和治疗年份后,发病至治疗时间≤90 分钟与 NIHSS 7-12 分的患者良好预后相关(比值比,1.37;95%置信区间,1.11-1.70;P=0.004),但与基线 NIHSS>12 分的患者(比值比,1.00;95%置信区间,0.76-1.32;P=0.99)和基线 NIHSS 0-6 分的患者(比值比,1.04;95%置信区间,0.78-1.39;P=0.80)无关。然而,在后一种情况下,当考虑改良 Rankin 量表 0 分为结局时(为了克服轻度症状患者的自发预后较好可能导致的天花板效应),发现了一个独立的相关性(比值比,1.51;95%置信区间,1.14-2.01;P<0.01)。超早期治疗与死亡率无关。
与后期溶栓相比,在症状发作后 90 分钟内进行静脉溶栓治疗,与中重度脑卒中患者的良好预后有强烈且独立的相关性。